An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this CME-certified Webcast and download the slides from a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR-positive, HER2-negative MBC in the context of an evolving treatment paradigm.
Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD
Sara Hurvitz, MD, FACP

Downloadable Slidesets

Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Joyce O'Shaughnessy, MD
Program Director
Released: May 31, 2019

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Sara Hurvitz, MD, FACP Released: May 31, 2019

Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including what to do after progression on a CDK4/6 inhibitor and a review of novel agents in the setting of resistance to standard-of-care therapies.

Adam M. Brufsky, MD, PhD Released: May 31, 2019

On-Demand Webcast

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR+/HER2- MBC, including the optimal application of CDK4/6 inhibitors, the evolving role of PI3K pathway blockade, promising strategies on the horizon for managing resistance, and panel case discussions.

Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD Sara Hurvitz, MD, FACP
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 5, 2019 Expiration: July 4, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?